Lung Therapeutics announced June 6 that it has completed a $14.3 million Series B financing round to support development of LTI-03, its lead therapy for idiopathic pulmonary fibrosis (IPF). LTI-03 has already showed promising results for other conditions including scleroderma and cardiac fibrosis. The funds will also support clinical trials, now underway in Australia and…
News
Overproduction of a protein called Sirtuin 6 (Sirt6) inhibits a cell process essential to the lung scarring seen in pulmonary fibrosis, according to a study. The finding suggests that scientists could use Sirt6 to develop therapies that prevent the disease. Scientists call the process that the finding applies to the epithelial to…
The death rate of pulmonary fibrosis patients who were put on a hospital ventilator was seven times higher than those treated without a ventilator, according to a review of thousands of medical records. The study of 22,350 admissions also showed that the cost of treating patients who were put on…
A $6.9 million grant will allow researchers at the University of Southern California Keck School of Medicine to delve deeper into the science of how air sac epithelial cells in the lungs regenerate. The research team, led by Zea Borok — a professor of medicine at Keck —…
A type of stem cell facilitates faulty signals that lead to the tiny lung-vessel dysfunction in pulmonary fibrosis (PF) and other respiratory diseases, a study indicates. The stem cells, known as mesenchymal progenitor cells, or MPCs, have the ability to evolve into other kinds of cells, including bone, cartilage, muscle…
The Pulmonary Fibrosis Foundation (PFF) say 1,000 people have enrolled on its PFF Patient Registry, an initiative to track data from PF patients nationwide. The registry will help researchers better understand pulmonary fibrosis by compiling data on disease progression, patient profiles and efficacy of available treatments. Enrollment is on track to…
Veracyte presented pivotal clinical validation data on the performance of its Envisia Genomic Classifier to diagnose idiopathic pulmonary fibrosis (IPF) at the American Thoracic Society (ATS) 2017 International Conference, held May 19-24 in Washington, D.C. IPF, a type of interstitial lung disease (ILD), is often challenging to diagnose. Each year, doctors in…
https://www.youtube.com/watch?v=dpUNgYbsQms If you have a chronic illness, you know just how much energy it takes to complete your daily chores and common household tasks. In this video from newlifeoutlook, Jennifer shares some practical tips to help make life a little easier for anyone suffering from a chronic illness. MORE: Nine tips…
Almost 37 percent of idiopathic pulmonary fibrosis patients who took Ofev for a year had no decline in a key measure of lung function, double the 18 percent of those on a placebo, according to one of three recent Ofev presentations in Washington. The results of that study applied to a…
Patients with idiopathic pulmonary fibrosis (IPF) want more information from their doctors at diagnosis, according to the results of a new survey. Researchers said that only half of patients surveyed report discussing antifibrotic treatment decisions with their doctors when they’re diagnosed. Results of the survey study, titled “Differences in…
